Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Corcept Therapeutics (CORT) FCF Margin: 2009-2025

Historic FCF Margin for Corcept Therapeutics (CORT) over the last 12 years, with Sep 2025 value amounting to 26.24%.

  • Corcept Therapeutics' FCF Margin fell 1302.00% to 26.24% in Q3 2025 from the same period last year, while for Sep 2025 it was 22.01%, marking a year-over-year decrease of 60.00%. This contributed to the annual value of 29.02% for FY2024, which is 271.00% up from last year.
  • According to the latest figures from Q3 2025, Corcept Therapeutics' FCF Margin is 26.24%, which was up 16.26% from 22.57% recorded in Q2 2025.
  • In the past 5 years, Corcept Therapeutics' FCF Margin registered a high of 50.50% during Q3 2021, and its lowest value of 3.20% during Q1 2025.
  • In the last 3 years, Corcept Therapeutics' FCF Margin had a median value of 24.89% in 2024 and averaged 24.79%.
  • Its FCF Margin has fluctuated over the past 5 years, first slumped by 3,085bps in 2022, then soared by 2,848bps in 2024.
  • Corcept Therapeutics' FCF Margin (Quarterly) stood at 49.95% in 2021, then slumped by 1,758bps to 32.37% in 2022, then tumbled by 2,802bps to 4.35% in 2023, then spiked by 2,848bps to 32.83% in 2024, then slumped by 1,302bps to 26.24% in 2025.
  • Its FCF Margin was 26.24% in Q3 2025, compared to 22.57% in Q2 2025 and 3.20% in Q1 2025.